Gary Berner, MD
Adolescent Medicine · Springdale, ARNPI 1659639664
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $214 and has fallen 81.3% since, to $40 in 2025. That places this record below the midpoint for adolescent medicine clinicians in AR, where the typical reported total is $485.
Across 21 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$71
- Baxter Healthcare$63
- Supernus Pharmaceuticals, Inc.$40
- Corium, LLC$25
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$20
- Novo Nordisk$20
- plus $148 from 10 others
What the payments were for
- Food & beverage$386100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $71 |
| Baxter Healthcare | 2 | $63 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Corium, LLC | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Amgen | 1 | $12 |
| Organon | 1 | $12 |
How this compares
$386 in reported general payments places this provider in the 45th percentile of 20 adolescent medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 12 | $34,674 |
| FarxigaDapagliflozin Propanediol | 30 | $30,845 |
| TrulicityDulaglutide | 26 | $26,235 |
| OzempicSemaglutide | 19 | $21,730 |
| JardianceEmpagliflozin | 14 | $8,137 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $5,844 |
| Aripiprazole | 12 | $3,334 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 13 | $1,192 |
| Levetiracetam | 11 | $1,096 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 28 | $1,038 |
| Gabapentin | 58 | $633 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $611 |
| Duloxetine Hcl | 29 | $497 |
| Zolpidem Tartrate | 27 | $370 |
| Lisinopril | 77 | $330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $71 | $30,84530 claims |
| Lilly USA, LLCTrulicity | $13 | $26,23526 claims |
| Novo NordiskOzempic | $20 | $21,73019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 20 adolescent medicine providers in Arkansas.
Other adolescent medicine in Springdale
- Stephanie LowrySpringdale$1K
- Joy HillBentonville$4K
- George SchaeferBentonville$2K
- James SchererBentonville$1K
- Carl EngmannBentonville$1K
- Joel FankhauserRogers$988
- Shannon JewellBentonville$915
- Loren AllenRogers$906
- Renee JonesBrinkley$672
- James CowanWest Memphis$485
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.